A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors. Lifileucel led to ...
A father-of-two with a rare form of cancer hopes his family's experience will help people start conversations with their ...
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year ...
Treatment-free survival after immunotherapy discontinuation in advanced melanoma: A systematic review and meta-analysis of real-world studies. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Researchers review melanoma subtypes, focusing on therapeutic advances in metastatic ocular melanoma, including TILs, ImmTACs, and targeted therapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback